# Galapagos

Source: https://onco.cc/companies/galapagos/  
OnCo record `galapagos` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Galapagos is a biotech pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites; it restructured its cell-therapy business in 2025.

## Summary

Galapagos, based in Mechelen, Belgium, and listed as GLPG, is a biotechnology company pursuing decentralised, seven-day vein-to-vein CAR-T manufacturing at hospital sites, and it restructured its cell therapy business in 2025. It uses Lonza's Cocoon platform at partner hospitals to make GLPG5101, a CD19 CAR-T, and GLPG5201, and in 2025 it announced a separation of the cell therapy unit and a strategic review; the record notes that its current corporate status should be verified before citing. OnCo links it to point-of-care and decentralised cell manufacturing. Whether hospital-based manufacturing can meet regulatory standards at scale is the question its model was built to test, and its restructuring shows how hard the business case is. The decentralised manufacturing page carries the wider field.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: supporting
- HQ: Mechelen
- Type: biotech
- Website: https://www.glpg.com
- Ticker: GLPG

## Sources

- Official website: https://www.glpg.com

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Point-of-care and decentralised cell manufacturing](https://onco.cc/technologies/point-of-care-cell-manufacturing/)
- trials: [Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies](https://onco.cc/trials/nct06652633/)

---
JSON: https://onco.cc/api/v1/entities/galapagos.json